News Novartis' Arzerra gains CLL approval Development partner Genmab says drug approved in relapsed disease.
News UK grants patients early access to AbbVie/Roche leukaemia dr... Venetoclax still under review in Europe.
Clinical AbbVie/Roche's Venclexta produces complete remission in 10% ... AbbVie/Roche's Venclexta (venetoclax) has produced a high overall response rate in chronic lymphocytic leukaemia patients with the 17p deletion mutation, a sub-group who do not respond well
Views & Analysis Obstacles to true patient centricity in Europe Campaigner and cancer patient Andrew Schorr says pharma needs to knock down the barriers to greater patient influence.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.